Artur Vardanyan
General Practice · Glendale, CANPI 1497073084
Payments from drug & device makers
Across 129 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$701
- Shield Therapeutics Inc$479
- Amgen$175
- Boehringer Ingelheim$165
- Lilly USA, LLC$145
- Pfizer$129
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,851100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $701 |
| Shield Therapeutics Inc | 19 | $479 |
| Amgen | 8 | $175 |
| Boehringer Ingelheim | 7 | $165 |
| Lilly USA, LLC | 5 | $145 |
| Pfizer | 6 | $129 |
| Ardelyx, Inc. | 4 | $113 |
| Merck | 5 | $99 |
| Vertiflex, Inc. | 6 | $95 |
| AstraZeneca | 4 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Aimmune Therapeutics, Inc. | 3 | $70 |
| Novartis | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| GSK | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $46 |
| Bayer | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $40 |
| UCB, Inc. | 1 | $31 |
| Hologic Sales And Service, LLC | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $16 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$125
How this compares
$2,865 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $70,549 |
| VascepaIcosapent Ethyl | 126 | $40,026 |
| LinzessLinaclotide | 61 | $35,262 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 18 | $34,370 |
| JanuviaSitagliptin Phosphate | 37 | $21,069 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $19,243 |
| TradjentaLinagliptin | 26 | $17,165 |
| TrulicityDulaglutide | 17 | $14,869 |
| EliquisApixaban | 15 | $14,176 |
| CreonLipase/Protease/Amylase | 12 | $13,572 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,490 |
| Icosapent Ethyl | 63 | $7,361 |
| Repatha SureclickEvolocumab | 11 | $6,866 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,601 |
| Dexlansoprazole DrDexlansoprazole | 36 | $5,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $165 | $87,714142 claims |
| AbbVieLinzess, Creon | $701 | $48,83473 claims |
| MerckJanuvia, Janumet | $99 | $40,31270 claims |
| Lilly USA, LLCTrulicity | $145 | $14,86917 claims |
| PfizerEliquis | $129 | $14,17615 claims |
| GSKBreo Ellipta | $48 | $9,49022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.
Other general practice in Glendale
- Marina GoldGlendale$784K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.